Outcome of patients with mantle cell lymphoma is not influenced by vascular endothelial growth factor polymorphisms.

摘要

Notwithstanding the most recent and effective therapeutic strategies, in the majority of patients mantle cell lymphoma (MCL) is still aggressive, with median overall survival (OS) ranging from 26 to 57 months, when patients are stratified according to the mantle cell lymphoma international prognostic index (MIPI) [1,2]. Thus, several immunochemotherapy combinations have been explored to improve outcome, such as R-Hyper-CVAD (rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine) [2], R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone) [3], maxi-CHOP [4], bortezomib plus R-CHOP [5], and mTOR (mammalian target of rapamycin) inhibitors [6]. Moreover, also autologous transplant still remains a valid therapeutic option for young patients responsive to dose-intensified induction chemotherapy, with 6-year overall survival and progression-free survival of 70% and 66%, respectively [7].